Kachnic LA, Moughan J, Hong TS, Haddock MG, et al. Patient-reported outcomes in NRG Oncology RTOG 1010: Phase 3 trial evaluating the addition of trastuzumab to trimodality treatment of HER2 overexpressing esophageal adenocarcinoma. Cancer 2026;132:e70345.
PMID: 41808581